5CCM | pdb_00005ccm

Crystal structure of SMYD3 with SAM and EPZ030456


Experimental Data Snapshot

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.30 Å
  • R-Value Free: 
    0.255 (Depositor), 0.252 (DCC) 
  • R-Value Work: 
    0.201 (Depositor), 0.205 (DCC) 
  • R-Value Observed: 
    0.203 (Depositor) 

wwPDB Validation 3D Report Full Report

Validation slider image for 5CCM

Ligand Structure Quality Assessment 


This is version 1.2 of the entry. See complete history

Literature

Novel Oxindole Sulfonamides and Sulfamides: EPZ031686, the First Orally Bioavailable Small Molecule SMYD3 Inhibitor.

Mitchell, L.H.Boriack-Sjodin, P.A.Smith, S.Thomenius, M.Rioux, N.Munchhof, M.Mills, J.E.Klaus, C.Totman, J.Riera, T.V.Raimondi, A.Jacques, S.L.West, K.Foley, M.Waters, N.J.Kuntz, K.W.Wigle, T.J.Scott, M.P.Copeland, R.A.Smith, J.J.Chesworth, R.

(2016) ACS Med Chem Lett 7: 134-138

  • DOI: https://doi.org/10.1021/acsmedchemlett.5b00272
  • Primary Citation Related Structures: 
    5CCL, 5CCM

  • PubMed Abstract: 

    SMYD3 has been implicated in a range of cancers; however, until now no potent selective small molecule inhibitors have been available for target validation studies. A novel oxindole series of SMYD3 inhibitors was identified through screening of the Epizyme proprietary histone methyltransferase-biased library. Potency optimization afforded two tool compounds, sulfonamide EPZ031686 and sulfamide EPZ030456, with cellular potency at a level sufficient to probe the in vitro biology of SMYD3 inhibition. EPZ031686 shows good bioavailability following oral dosing in mice making it a suitable tool for potential in vivo target validation studies.


  • Organizational Affiliation
    • Epizyme Inc. , Fourth Floor, 400 Technology Square, Cambridge, Massachusetts 02139, United States.

Macromolecule Content 

  • Total Structure Weight: 50.32 kDa 
  • Atom Count: 3,582 
  • Modeled Residue Count: 423 
  • Deposited Residue Count: 428 
  • Unique protein chains: 1

Macromolecules

Find similar proteins by:|  3D Structure
Entity ID: 1
MoleculeChains  Sequence LengthOrganismDetailsImage
Histone-lysine N-methyltransferase SMYD3428Homo sapiensMutation(s): 0 
Gene Names: SMYD3ZMYND1ZNFN3A1
EC: 2.1.1.43 (PDB Primary Data), 2.1.1.354 (UniProt)
UniProt & NIH Common Fund Data Resources
Find proteins for Q9H7B4 (Homo sapiens)
Explore Q9H7B4 
Go to UniProtKB:  Q9H7B4
PHAROS:  Q9H7B4
GTEx:  ENSG00000185420 
Entity Groups
Sequence Clusters30% Identity50% Identity70% Identity90% Identity95% Identity100% Identity
UniProt GroupQ9H7B4
Sequence Annotations
Expand
Reference Sequence

Small Molecules

Binding Affinity Annotations 
IDSourceBinding Affinity
4ZX BindingDB:  5CCM Ki: min: 1.3, max: 4.7 (nM) from 2 assay(s)
IC50: min: 2.58, max: 48 (nM) from 3 assay(s)

Experimental Data & Validation

Experimental Data

  • Method: X-RAY DIFFRACTION
  • Resolution: 2.30 Å
  • R-Value Free:  0.255 (Depositor), 0.252 (DCC) 
  • R-Value Work:  0.201 (Depositor), 0.205 (DCC) 
  • R-Value Observed: 0.203 (Depositor) 
Space Group: P 21 21 21
Unit Cell:
Length ( Å )Angle ( ˚ )
a = 60.484α = 90
b = 65.852β = 90
c = 107.358γ = 90
Software Package:
Software NamePurpose
HKL-2000data reduction
SCALEPACKdata scaling
REFMACrefinement
PDB_EXTRACTdata extraction

Structure Validation

View Full Validation Report



Ligand Structure Quality Assessment 


Entry History 

Deposition Data

Revision History  (Full details and data files)

  • Version 1.0: 2015-09-09
    Type: Initial release
  • Version 1.1: 2016-03-30
    Changes: Database references
  • Version 1.2: 2024-03-06
    Changes: Data collection, Database references, Derived calculations